Filing Details
- Accession Number:
- 0001209191-18-024991
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-04-16 16:24:58
- Reporting Period:
- 2018-04-12
- Accepted Time:
- 2018-04-16 16:24:58
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 908259 | Mateon Therapeutics Inc | MATN | Biological Products, (No Disgnostic Substances) (2836) | 133679168 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1687930 | Rogers Donald Reynolds | C/O Mateon Therapeutics, Inc. 701 Gateway Blvd., Suite 210 South San Francisco CA 94080 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-04-12 | 250,000 | $0.00 | 280,000 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Common Stock A Warrants (Right to Buy) | Acquisiton | 2018-04-12 | 125,000 | $0.00 | 125,000 | $0.40 |
| Common Stock | Common Stock B Warrants (Right to Buy) | Acquisiton | 2018-04-12 | 125,000 | $0.00 | 125,000 | $0.40 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 125,000 | 2018-04-12 | 2020-04-12 | No | 4 | P | Direct |
| 125,000 | No | 4 | P | Direct |
Footnotes
- The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the "Company"), dated April 12, 2018 (the "Subscription Agreement"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the "Common Stock"), (ii) an "A" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a "B" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share.
- The Common Stock B Warrants shall become exercisable immediately following the Company's stockholders' approval of an increase in the number of the Company's authorized shares of Common Stock sufficient to cover the number of shares issuable upon the exercise of all of the Common Stock B Warrants issued pursuant to the Subscription Agreement (the "Stock Authorization"). The Company is obligated to effect the Stock Authorization no later than June 30, 2018 (the "Authorization Date").
- The Common Stock B Warrants shall expire on the date that is two years after the Stock Authorization is effected (the "Expiration Date"). In the event that the Company fails to effect the Stock Authorization by the Authorization Date, the Expiration Date will be extended for two additional years.
Billionaire Hedge Funds
